Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease
Completed
- Conditions
- Invasive Pneumococcal Disease
- Interventions
- Other: No intervention
- Registration Number
- NCT01128439
- Lead Sponsor
- Pfizer
- Brief Summary
This study will estimate the incidence of invasive pneumococcal disease in members of the Northern Kaiser Permanente healthcare system during each of the 5 following introduction of Prevnar 13.
- Detailed Description
No sampling as no subjects are enrolled
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
- Documented invasive pneumococcal disease (IPD), defined as recovery of an isolate of S pneumoniae from a normally sterile site in a member of the surveillance population.
Exclusion Criteria
None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 1 No intervention -
- Primary Outcome Measures
Name Time Method Incidence of IPD in the NCKP healthcare system in children 6 weeks through 5 years of age (prior to the sixth birthday) during each of the 5 years following introduction of Prevnar 13. 5 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Kaiser Permanente Vaccine Study Center
🇺🇸Oakland, California, United States